Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity

mAbs

Volumn 4, Issue 1, 2012, Pages 57-68

  Liu, Xiao Yun ^a   Pop, Laurentiu M ^a   Schindler, John ^a   Vitetta, Ellen S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anti CD22; Chimeric; Fc mutations; Immunotoxins; Monoclonal antibody; Ricin A chain

Indexed keywords

FC RECEPTOR; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RBF4; RECOMBINANT RICIN TOXIN A; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DAUDI CELL; DRUG HALF LIFE; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LYMPHOMA CELL LINE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; VASCULAR DISEASE;

AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD22; CELL LINE, TUMOR; CHILD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOTOXINS; LYMPHOMA, NON-HODGKIN; MICE; MUTATION; RECOMBINANT PROTEINS; RICIN;

EID: 84863025438     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.4.1.18348     Document Type: Article

References (45)

1. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58:221-37; PMID:17059365; http://dx.doi.org/10.1146/ annurev.med.58.070605.115320.
2. Fodstad O, Kvalheim G, Godal A, Lotsberg J, Aamdal S, Høst H, et al. Phase I study of the plant protein ricin. Cancer Res 1984; 44:862-5; PMID:6692385.
3. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18:1622-36; PMID:10764422.
4. Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, et al. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res 1988; 48:6396-403; PMID:3263186.
5. Herrera L, Bostrom B, Gore L, Sandler E, Lew G, Schlegel PG, et al. A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009; 31:936-41; PMID:19875969; http://dx.doi.org/10.1097/MPH.0b013e3181bdf211.
6. Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002; 8:1779-86; PMID:12060617.
7. Schnell R, Vitetta E, Schindler J, Borchmann P, Barth S, Ghetie V, et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 2000; 14:129-35; PMID:10637488; http://dx.doi.org/10.1038/sj.leu.2401626.
8. Lynch TJ Jr, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, et al. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol 1997; 15:723-34; PMID:9053498.
9. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993; 82:2624-33; PMID:8219217.
10. Avarbock AB, Loren AW, Park JY, Junkins-Hopkins JM, Choi J, Litzky LA, et al. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis. Am J Hematol 2008; 83:593-5; PMID:18335564; http://dx.doi.org/10.1002/ajh.21180.
11. Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002; 8:3092-9; PMID:12374676.
12. Schindler J, Sausville E, Messmann R, Uhr JW, Vitetta ES. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res 2001; 7:255-8; PMID:11234876.
13. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin- 2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci USA 1999; 96:3957-62; PMID:10097145; http://dx.doi.org/10.1073/pnas.96. 7.3957.
14. Lindstrom AL, Erlandsen SL, Kersey JH, Pennell CA. An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers. Blood 1997; 90:2323-34; PMID:9310483.
15. Siegall CB, Liggitt D, Chace D, Tepper MA, Fell HP. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci USA 1994; 91:9514-8; PMID:7937798; http://dx.doi.org/10.1073/pnas.91.20.9514.
16. Baluna R, Coleman E, Jones C, Ghetie V, Vitetta ES. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp Cell Res 2000; 258:417-24; PMID:10896793; http://dx.doi.org/10.1006/excr.2000.4954.
17. Smallshaw JE, Ghetie V, Rizo J, Fulmer JR, Trahan LL, Ghetie MA, et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol 2003; 21:387-91; PMID:12627168; http://dx.doi.org/10.1038/ nbt800.
18. Sharkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood 2009; 113:3891-5; PMID:19182204; http://dx.doi.org/10.1182/blood-2008-11-188896.
19. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphomas grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res 1991; 51:5876-80; PMID:1933855.
20. Borvak J, Richardson J, Medesan C, Antohe F, Radu C, Simionescu M, et al. Functional expression of the MHC class I-related receptor, FcRn, in the endothelial cells of mice. Int Immunol 1998; 10:1289-98; PMID:9786428; http://dx.doi.org/10.1093/intimm/10.9.1289.
21. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 2000; 18:739-66; PMID:10837074; http://dx.doi.org/10.1146/annurev.immunol.18.1.739.
22. Pop LM, Liu X, Ghetie V, Vitetta ES. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life. Int Immunopharmacol 2005; 5:1279-90; PMID:15914332; http://dx.doi.org/10.1016/j.intimp.2005.03.013.
23. Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol 1997; 158:2211-7; PMID:9036967.
24. Kim JK, Firan M, Caius RG, Kin CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 1999; 29:2819-25; PMID:10508256; http://dx.doi.org/10.1002/(SICI)1521- 4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6.
25. Martin WL, West AP Jr, Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001; 7:867-77; PMID:11336709; http://dx.doi.org/10.1016/S1097-2765(01)00230-1.
26. van Horssen PJ, van Oosterhout YV, de Witte T, Preijers FW. Cytotoxic potency of CD22-ricin A depends on intracellular routing rather than on the number of internalized molecules. Scand J Immunol 1995; 41:563-9; PMID:7770726; http://dx.doi.org/10.1111/j.1365-3083.1995.tb03608.x.
27. van Oosterhout YV, van den Herik-Oudijk IE, Wessels HM, de Witte T, van de Winkel JG, Preijers FW. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. Cancer Res 1994; 54:3527-32; PMID:7516821.
28. Firan M, Bawdon R, Radu C, Ober RJ, Eaken D, Antohe F, et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol 2001; 13:993-1002; PMID:11470769; http://dx.doi.org/10.1093/intimm/13.8.993.
29. Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005; 65:622-31; PMID:15695407.
30. Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, et al. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res 2007; 67:718-26; PMID:17234783; http://dx.doi.org/10.1158/0008-5472. CAN-06-0454.
31. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 2004; 279:6213-6; PMID:14699147; http://dx.doi.org/10.1074/jbc.C300470200.
32. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514-24; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200.
33. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663-71; PMID:19494290; http://dx.doi.org/10.4049/jimmunol.0804182.
34. Gillies SD, Lo KM, Burger C, Lan Y, Dahl T, Wong WK. Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin Cancer Res 2002; 8:210-6; PMID:11801561.
35. Kim JK, Tsen MF, Ghetie V, Ward ES. Evidence that the hinge region plays a role in maintaining serum levels of the murine IgG1 molecule. Mol Immunol 1995; 32:467-75; PMID:7783750; http://dx.doi.org/10.1016/0161-5890(95)00019-B.
36. Ghetie MA, Uhr J, Vitetta ES. Covalent binding of human a2-macroglobulin to deglycosylated ricin A chain and its immunotoxins. Cancer Res 1991; 51:1482-7; PMID:1705175.
37. Ghetie V, Ward ES, Vitetta ES. Pharmacokinetics of antibodies and immunotoxins in mice and humans. In: Figg WD, MsLeod H, Ed. Handbook of anticancer pharmacokinetics and pharmacodynamics. Humana Press 2004; 475-98.
38. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009; 113:3792-800; PMID:18988862; http://dx.doi.org/10.1182/blood-2008-08-173195.
39. Rosenblum MG, Cheung LH, Liu Y, Marks JW, 3rd. Design, expression, purification and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 2003; 63:3995-4002; PMID:12873997.
40. Woo JH, Lee YJ, Neville DM, Frankel AE. Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials. Methods Mol Biol 2010; 651:157-75; PMID:20686966; http://dx.doi.org/10.1007/978-1-60761-786-0-10.
41. Tazzari PL, Polito L, Bolognesi A, Pistillo MP, Capanni P, Palmisano GL, et al. Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model. J Immunol 2001; 167:4222-9; PMID:11591743.
42. Alderson RF, Kreitman RJ, Chen T, Yeung P, Herbst R, Fox JA, et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res 2009; 15:832-9; PMID:19188153; http://dx.doi.org/10.1158/1078-0432.CCR-08-1456.
43. Liu Y, Zhang W, Cheung LH, Niu T, Wu Q, Li C, et al. The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts. Neoplasia 2006; 8:384-93; PMID:16790087; http://dx.doi.org/10.1593/neo.06121.
44. Liu XY, Pop LM, Tsai L, Pop IV, Vitetta ES. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines. Int J Cancer 2011; 129:497-506; PMID:20878959; http://dx.doi.org/10.1002/ijc.25695.
45. O'Hare M, Roberts LM, Thorpe PE, Watson GJ, Prior B, Lord JM. Expression of ricin A chain in Escherichia coli. FEBS Lett 1987; 216:73-8; PMID:3556218; http://dx.doi.org/10.1016/0014-5793(87)80759-7.